BJC Reports,
Journal Year:
2025,
Volume and Issue:
3(1)
Published: Jan. 27, 2025
Osteosarcoma
is
the
most
common
malignant
bone
tumour
with
limited
treatment
options
and
poor
outcomes
in
advanced
metastatic
cases.
Current
immunotherapies
show
efficacy,
highlighting
need
for
novel
therapeutic
approaches.
Systemic
immune
activation
by
Toll-like
receptor
4
(TLR4)
immunostimulants
has
shown
great
promise;
however,
current
TLR4
agonists'
toxicity
hinders
this
systemic
approach
patients
osteosarcoma.
We
compared
antitumour
effect
of
lipopolysaccharides
(LPS)
that
an
innovative
chemically
detoxified
agonist
(Lipo-MP-LPS)
a
syngeneic
osteosarcoma
mouse
model.
Lipo-MP-LPS
exhibited
optimal
safety
solubility
profile
administration
at
effective
dose.
evaluated
growth,
lung
metastases,
cell
infiltration
wild-type
TLR4-mutant
mice
performed
selective
immunodepletion.
effects
against
localised
tumours
like
those
natural
LPS.
promoted
CD8+
T
cells
M1
macrophages
primary
M1-phenotype
macrophage
shift.
The
were
found
to
depend
on
cells,
but
not
macrophages.
inhibited
growth
metastasis
promoting
CD8
+
infiltration,
indicating
its
potential
Biomarker Research,
Journal Year:
2023,
Volume and Issue:
11(1)
Published: Nov. 28, 2023
Abstract
Today,
adoptive
cell
therapy
has
many
successes
in
cancer
therapy,
and
this
subject
is
brilliant
using
chimeric
antigen
receptor
T
cells.
The
CAR
with
its
FDA-approved
drugs,
could
treat
several
types
of
hematological
malignancies
thus
be
very
attractive
for
treating
solid
cancer.
Unfortunately,
the
cannot
functional
cancers
due
to
unique
features.
This
treatment
method
harmful
adverse
effects
that
limit
their
applications,
so
novel
treatments
must
use
new
cells
like
NK
cells,
NKT
macrophage
Among
these
innate
features,
are
more
tumor
seem
a
better
candidate
prior
methods.
have
vital
roles
microenvironment
and,
direct
effect,
can
eliminate
efficiently.
In
addition,
being
part
immune
system,
attended
sites.
With
high
infiltration,
modulations
effective.
review
investigates
last
achievements
CAR-macrophage
future
immunotherapy
method.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: June 1, 2024
Abstract
Significant
advancements
have
been
made
in
the
application
of
chimeric
antigen
receptor
(CAR)-T
treatment
for
blood
cancers
during
previous
ten
years.
However,
its
effectiveness
treating
solid
tumors
is
still
lacking,
necessitating
exploration
alternative
immunotherapies
that
can
overcome
significant
challenges
faced
by
current
CAR-T
cells.
CAR-based
immunotherapy
against
shows
promise
with
emergence
macrophages,
which
possess
robust
phagocytic
abilities,
antigen-presenting
functions,
and
ability
to
modify
tumor
microenvironment
stimulate
adaptive
responses.
This
paper
presents
a
thorough
examination
latest
progress
CAR-M
therapy,
covering
both
basic
scientific
studies
clinical
trials.
study
examines
primary
obstacles
hindering
realization
complete
potential
as
well
strategies
be
employed
these
hurdles.
With
revolutionary
technologies
like
situ
genetic
modification,
synthetic
biology
techniques,
biomaterial-supported
gene
transfer,
provide
wider
array
resources
manipulating
tumor-associated
we
suggest
combining
advanced
methods
will
result
creation
new
era
therapy
demonstrates
improved
efficacy,
safety,
availability.
Graphical
Journal of Hematology & Oncology,
Journal Year:
2025,
Volume and Issue:
18(1)
Published: Jan. 13, 2025
The
tumor
microenvironment
(TME)
is
integral
to
cancer
progression,
impacting
metastasis
and
treatment
response.
It
consists
of
diverse
cell
types,
extracellular
matrix
components,
signaling
molecules
that
interact
promote
growth
therapeutic
resistance.
Elucidating
the
intricate
interactions
between
cells
TME
crucial
in
understanding
progression
challenges.
A
critical
process
induced
by
epithelial-mesenchymal
transition
(EMT),
wherein
epithelial
acquire
mesenchymal
traits,
which
enhance
their
motility
invasiveness
progression.
By
targeting
various
components
TME,
novel
investigational
strategies
aim
disrupt
TME's
contribution
EMT,
thereby
improving
efficacy,
addressing
resistance,
offering
a
nuanced
approach
therapy.
This
review
scrutinizes
key
players
emphasizing
avenues
therapeutically
components.
Moreover,
article
discusses
implications
for
resistance
mechanisms
highlights
current
toward
modulation
along
with
potential
caveats.
Advanced Healthcare Materials,
Journal Year:
2023,
Volume and Issue:
12(26)
Published: Aug. 4, 2023
Abstract
The
application
of
nanomaterials
in
healthcare
has
emerged
as
a
promising
strategy
due
to
their
unique
structural
diversity,
surface
properties,
and
compositional
diversity.
In
particular,
have
found
significant
role
improving
drug
delivery
inhibiting
the
growth
metastasis
tumor
cells.
Moreover,
recent
studies
highlighted
potential
modulating
microenvironment
(TME)
enhancing
activity
immune
cells
improve
therapy
efficacy.
Various
types
are
currently
utilized
carriers,
immunosuppressants,
activators,
immunoassay
reagents,
more
for
immunotherapy.
Necessarily,
used
immunotherapy
can
be
grouped
into
two
categories:
organic
inorganic
nanomaterials.
Though
both
shown
ability
achieve
purpose
immunotherapy,
composition
properties
result
differences
mechanisms
modes
action.
Organic
further
divided
polymers,
cell
membranes,
nanoemulsion‐modified,
hydrogel
forms.
At
same
time,
broadly
classified
nonmetallic
metallic
current
work
aims
explore
action
these
different
prospects
promoting
Cell Death and Disease,
Journal Year:
2024,
Volume and Issue:
15(5)
Published: May 2, 2024
Abstract
Cancer
immunotherapy
has
rapidly
transformed
cancer
treatment,
yet
resistance
remains
a
significant
hurdle,
limiting
its
efficacy
in
many
patients.
Circular
RNAs
(circRNAs),
novel
class
of
non-coding
RNAs,
have
emerged
as
pivotal
regulators
gene
expression
and
cellular
processes.
Increasing
evidence
indicates
their
involvement
modulating
to
immunotherapy.
Notably,
certain
circRNAs
function
miRNA
sponges
or
interact
with
proteins,
influencing
the
immune-related
genes,
including
crucial
immune
checkpoint
molecules.
This,
turn,
shapes
tumor
microenvironment
significantly
impacts
response
In
this
comprehensive
review,
we
explore
evolving
role
orchestrating
immunotherapy,
specific
focus
on
mechanisms
expression.
Additionally,
underscore
potential
promising
therapeutic
targets
augment
effectiveness
Understanding
could
contribute
development
new
strategies
overcome
improve
patient
outcomes.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: April 12, 2024
Surgery,
chemotherapy,
and
endocrine
therapy
have
improved
the
overall
survival
postoperative
recurrence
rates
of
Luminal
A,
B,
HER2-positive
breast
cancers
but
treatment
modalities
for
triple-negative
cancer
(TNBC)
with
poor
prognosis
remain
limited.
The
effective
application
rapidly
developing
chimeric
antigen
receptor
(CAR)-T
cell
in
hematological
tumors
provides
new
ideas
cancer.
Choosing
suitable
specific
targets
is
crucial
applying
CAR-T
treatment.
In
this
paper,
we
summarize
therapy’s
potential
different
subtypes
based
on
existing
research
progress,
especially
TNBC.
CAR-based
immunotherapy
has
resulted
advancements
CAR-macrophages,
CAR-NK
cells,
CAR-mesenchymal
stem
cells
(MSCs)
may
be
more
safer
treating
solid
tumors,
such
as
However,
tumor
microenvironment
(TME)
side
effects
pose
challenges
to
immunotherapy.
cells-derived
exosomes
are
advantageous
therapy.
Exosomes
carrying
CAR
immense
value
provide
a
modality
good
effects.
review,
an
overview
development
discuss
progress
CAR-expressing
We
elaborate
TNBC
prospects
using
CAR-MSCs
Experimental Hematology and Oncology,
Journal Year:
2024,
Volume and Issue:
13(1)
Published: Aug. 5, 2024
Abstract
Chimeric
antigen
receptor
macrophage
(CAR-MΦ)
represents
a
significant
advancement
in
immunotherapy,
especially
for
treating
solid
tumors
where
traditional
CAR-T
therapies
face
limitations.
CAR-MΦ
offers
promising
approach
to
target
and
eradicate
tumor
cells
by
utilizing
macrophages’
phagocytic
antigen-presenting
abilities.
However,
challenges
such
as
the
complex
microenvironment
(TME),
variability
expression,
immune
suppression
limit
their
efficacy.
This
review
addresses
these
issues,
exploring
mechanisms
of
action,
optimal
construct
designs,
interactions
within
TME.
It
also
delves
into
ex
vivo
manufacturing
CAR-MΦ,
discussing
autologous
allogeneic
sources
importance
stringent
quality
control.
The
potential
synergies
integrating
with
existing
cancer
like
checkpoint
inhibitors
conventional
chemotherapeutics
are
examined
highlight
possible
enhanced
treatment
outcomes.
Furthermore,
regulatory
pathways
scrutinized
alongside
established
protocols
cells,
identifying
unique
considerations
essential
clinical
trials
market
approval.
Proposed
safety
monitoring
frameworks
aim
manage
adverse
events,
cytokine
release
syndrome,
crucial
patient
safety.
Consolidating
current
research
insights,
this
seeks
refine
therapeutic
applications,
overcome
barriers,
suggest
future
directions
transition
from
experimental
platforms
standard
care
options.
Journal of Advanced Research,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
After
significant
advancements
in
tumor
treatment,
personalized
cell
therapy
based
on
chimeric
antigen
receptors
(CAR)
holds
promise
for
transforming
the
management
of
various
diseases.
CAR-T
therapy,
first
approved
CAR
product,
has
demonstrated
therapeutic
potential
treating
infectious
diseases,
autoimmune
disorders,
and
fibrosis.
CAR-macrophages
(CAR-Ms)
are
emerging
as
a
promising
approach
immune
particularly
solid
highlighting
feasibility
using
macrophages
to
eliminate
pathogens
abnormal
cells.
